{
  "id": 16183888,
  "title": "Broker’s Call: SRF (Buy)",
  "url": "https://urgent.news/2026/10/23/brokers-call-srf-buy",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-23T11:37:04.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/brokers-call-srf-buy/article71615900.ece"
  },
  "original_language": "en",
  "account": "SRF reported a 35% year-on-year revenue growth, which was in line with market expectations. However, profitability fell short of estimates due to rising input costs. The company's chemical business saw a 25% revenue increase, propelled by strong performance in the ref gas segment, while PFB revenue grew by 51%, driven by improved realization of raw material costs. Technical textiles also grew by 26%. Management maintained its FY27 revenue growth forecast of 15-20% and raised expectations for the latter half of the year, citing firm pricing of ref gas and increased volumes in specialty chemicals. However, the company warned of near-term margin pressures due to high costs of raw materials, freight, and energy, with limited ability to pass these costs onto customers. Despite these challenges, long-term growth opportunities persist, particularly through scale-up in fluoropolymer products, new Odisha HFO plant, expanding pharma and agrochemical pipelines, and an increasing focus on emerging industries. The broker has lowered EPS estimates for FY27, FY28, and FY29 by -8%, -5%, and -9%, respectively. With a revised target price of ₹2,800 based on H1FY29 earnings (derived PE of 30x on H1FY29 EPS), the broker maintains a BUY rating for SRF.",
  "summary": "Antique Stock Broking",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}